101 related articles for article (PubMed ID: 1703237)
1. Phase I clinical and pharmacokinetic trial of flavone acetic acid.
Havlin KA; Kuhn JG; Craig JB; Boldt DH; Weiss GR; Koeller J; Harman G; Schwartz R; Clark GN; Von Hoff DD
J Natl Cancer Inst; 1991 Jan; 83(2):124-8. PubMed ID: 1703237
[TBL] [Abstract][Full Text] [Related]
2. Phase I and pharmacokinetic study of flavone acetic acid.
Kerr DJ; Kaye SB; Cassidy J; Bradley C; Rankin EM; Adams L; Setanoians A; Young T; Forrest G; Soukop M
Cancer Res; 1987 Dec; 47(24 Pt 1):6776-81. PubMed ID: 3677106
[TBL] [Abstract][Full Text] [Related]
3. Phase I and pharmacology study of flavone acetic acid administered two or three times weekly without alkalinization.
de Forni M; Chabot GG; Armand JP; Gouyette A; Klink-Alak M; Recondo G
Cancer Chemother Pharmacol; 1995; 35(3):219-24. PubMed ID: 7805180
[TBL] [Abstract][Full Text] [Related]
4. Phase I and clinical pharmacology study of intravenous flavone acetic acid (NSC 347512).
Weiss RB; Greene RF; Knight RD; Collins JM; Pelosi JJ; Sulkes A; Curt GA
Cancer Res; 1988 Oct; 48(20):5878-82. PubMed ID: 3167843
[TBL] [Abstract][Full Text] [Related]
5. Clinical and pharmacokinetic phase I trial with the diethylaminoester of flavone acetic acid (LM985, NSC 293015).
Dodion PF; Abrams J; Gérard B; Crespeigne N; Peeters B; Van Berchem C; Kenis Y
Eur J Cancer Clin Oncol; 1987 Jun; 23(6):837-42. PubMed ID: 3653200
[TBL] [Abstract][Full Text] [Related]
6. A phase I and pharmacokinetic study of 12-h infusion of flavone acetic acid.
Olver IN; Webster LK; Bishop JF; Stokes KH
Cancer Chemother Pharmacol; 1992; 29(5):354-60. PubMed ID: 1551173
[TBL] [Abstract][Full Text] [Related]
7. Phase I study of flavone acetic acid (NSC 347512, LM975) in patients with pediatric malignant solid tumors.
Pratt CB; Relling MV; Meyer WH; Douglass EC; Kellie SJ; Avery L
Am J Clin Oncol; 1991 Dec; 14(6):483-6. PubMed ID: 1957836
[TBL] [Abstract][Full Text] [Related]
8. Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms.
Senderowicz AM; Headlee D; Stinson SF; Lush RM; Kalil N; Villalba L; Hill K; Steinberg SM; Figg WD; Tompkins A; Arbuck SG; Sausville EA
J Clin Oncol; 1998 Sep; 16(9):2986-99. PubMed ID: 9738567
[TBL] [Abstract][Full Text] [Related]
9. Characterization of the major metabolites of flavone acetic acid and comparison of their disposition in humans and mice.
Cummings J; Double JA; Bibby MC; Farmer P; Evans S; Kerr DJ; Kaye SB; Smyth JF
Cancer Res; 1989 Jul; 49(13):3587-93. PubMed ID: 2731178
[TBL] [Abstract][Full Text] [Related]
10. Phase I clinical and pharmacological study of merbarone.
Dimaggio JJ; Warrell RP; Muindi J; Stevens YW; Lee SJ; Lowenthal DA; Haines I; Walsh TD; Baltzer L; Yaldaei S
Cancer Res; 1990 Feb; 50(4):1151-5. PubMed ID: 2297763
[TBL] [Abstract][Full Text] [Related]
11. Phase I and pharmacokinetic study of LM985 (flavone acetic acid ester).
Kerr DJ; Kaye SB; Graham J; Cassidy J; Harding M; Setanoians A; McGrath JC; Vezin WR; Cunningham D; Forrest G
Cancer Res; 1986 Jun; 46(6):3142-6. PubMed ID: 3698028
[TBL] [Abstract][Full Text] [Related]
12. Phase I clinical and pharmacokinetic study of flavopiridol in children with refractory solid tumors: a Children's Oncology Group Study.
Whitlock JA; Krailo M; Reid JM; Ruben SL; Ames MM; Owen W; Reaman G;
J Clin Oncol; 2005 Dec; 23(36):9179-86. PubMed ID: 16361620
[TBL] [Abstract][Full Text] [Related]
13. Flavone acetic acid: a nonlinear pharmacokinetic model.
Gouyette A; Kerr DJ; Kaye SB; Setanoians A; Cassidy J; Bradley C; Forrest G; Soukop M
Cancer Chemother Pharmacol; 1988; 22(2):114-9. PubMed ID: 3409441
[TBL] [Abstract][Full Text] [Related]
14. Phase I clinical investigation of amonafide.
Saez R; Craig JB; Kuhn JG; Weiss GR; Koeller J; Phillips J; Havlin K; Harman G; Hardy J; Melink TJ
J Clin Oncol; 1989 Sep; 7(9):1351-8. PubMed ID: 2549205
[TBL] [Abstract][Full Text] [Related]
15. Etoposide bioavailability after oral administration of the prodrug etoposide phosphate in cancer patients during a phase I study.
Chabot GG; Armand JP; Terret C; de Forni M; Abigerges D; Winograd B; Igwemezie L; Schacter L; Kaul S; Ropers J; Bonnay M
J Clin Oncol; 1996 Jul; 14(7):2020-30. PubMed ID: 8683232
[TBL] [Abstract][Full Text] [Related]
16. CD16+ and CD56+ cells as markers of necrotizing and crescentic glomerulonephritis and active IgA glomerulonephropathy.
Hotta O; Seki S; Taguma Y; Shimoda A; Abo T; Takahashi H
Nephron; 1991; 57(2):239-40. PubMed ID: 1708443
[No Abstract] [Full Text] [Related]
17. Phase I trial and pharmacokinetic study of pyrazoloacridine in children and young adults with refractory cancers.
Berg SL; Blaney SM; Adamson PC; O'Brien M; Poplack DG; Arndt C; Blatt J; Balis FM
J Clin Oncol; 1998 Jan; 16(1):181-6. PubMed ID: 9440741
[TBL] [Abstract][Full Text] [Related]
18. Phase II trials with flavone acetic acid (NCS. 347512, LM975) in patients with advanced carcinoma of the breast, colon, head and neck and melanoma.
Kaye SB; Clavel M; Dodion P; Monfardini S; ten Bokkel-Huinink W; Wagener DT; Gundersen S; Stoter G; Smith J; Renard J
Invest New Drugs; 1990; 8 Suppl 1():S95-9. PubMed ID: 2380021
[TBL] [Abstract][Full Text] [Related]
19. Phase II trials of flavone acetic acid in advanced malignant melanoma and colorectal carcinoma.
Kerr DJ; Maughan T; Newlands E; Rustin G; Bleehen NM; Lewis C; Kaye SB
Br J Cancer; 1989 Jul; 60(1):104-6. PubMed ID: 2803908
[TBL] [Abstract][Full Text] [Related]
20. Phase I clinical and pharmacokinetic study of hexamethylene bisacetamide (NSC 95580) administered as a five-day continuous infusion.
Egorin MJ; Sigman LM; Van Echo DA; Forrest A; Whitacre MY; Aisner J
Cancer Res; 1987 Jan; 47(2):617-23. PubMed ID: 3791246
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
